mRNA Biomarkers in Dried Blood Spots May Improve Detection of Autologous Blood Micro‐Transfusions Using an Individualized Approach
Open Access
- 9 August 2025
- journal article
- Published by Wiley in Drug Testing and Analysis
- Vol. 17 (11) , 2291-2300
Abstract
Autologous blood transfusions (ABTs) are prohibited by the World Anti‐Doping Agency (WADA), yet detecting autologous blood micro‐transfusions (ABMTs) remains a challenge. Due to smaller transfused volumes, ABMTs cause attenuated biomarker changes, limiting detection sensitivity within the Athlete Biological Passport (ABP). This study assessed whether mRNA expression of 5‐aminolevulinic acid synthase ( ALAS2 ) and carbonic anhydrase 1 ( CA1 ), measured from dried blood spots (DBS), could serve as sensitive biomarkers of ABMT. In a randomized, placebo‐controlled design, 47 trained individuals (24 ♀; mean VO 2 peak 56 ± 7 mL·min −1 ·kg −1 ) were allocated to an ABMT group ( n = 23; ♀ = 12) or placebo group ( n = 24; ♀ = 12). The ABMT group donated 450 mL of blood and received a 130 mL packed red blood cell reinfusion 4 weeks later. Blood sampling occurred regularly before and after both donation and reinfusion. ALAS2 and CA1 mRNA expression from DBS, and reticulocyte percentage (RET%) from venous blood, were analyzed. Following blood donation, ALAS2 , CA1 , and RET% increased by 270%, 200%, and 150%, respectively. However, no consistent group‐level changes were observed after ABMT. Individualized analysis identified more outliers for ALAS2 than for CA1 , and blinded interpretation of individual mRNA profiles achieved > 95% sensitivity and specificity for detecting ABMT. These findings suggest that ALAS2 mRNA expression, assessed via minimally invasive DBS sampling, is a promising biomarker for identifying ABMT. This approach may enhance current anti‐doping strategies by improving sensitivity to small‐volume autologous transfusions that evade detection through traditional ABP biomarkers.Keywords
This publication has 35 references indexed in Scilit:
- RNA‐Based Biomarkers of Iron Metabolism in Dried Blood Spots for Detecting Recombinant Human Erythropoietin in Doping ControlDrug Testing and Analysis, 2025
- mRNA biomarkers sensitive and specific to micro‐dose erythropoietin treatment at sea level and altitudeDrug Testing and Analysis, 2024
- Variability of the urinary and blood steroid profiles in healthy and physically active women with and without oral contraceptionDrug Testing and Analysis, 2022
- Analysis of dried blood spots is a feasible alternative for detecting ephedrine in doping controlDrug Testing and Analysis, 2022
- No pain, just gain: Painless, easy, and fast dried blood spot collection from fingertip and upper arm in doping controlDrug Testing and Analysis, 2021
- The use of RNA‐based 5'‐aminolevulinate synthase 2 biomarkers in dried blood spots to detect recombinant human erythropoietin microdosesDrug Testing and Analysis, 2021
- Longitudinal evaluation of multiple biomarkers for the detection of testosterone gel administration in women with normal menstrual cycleDrug Testing and Analysis, 2021
- Antidoping: From health tests to the athlete biological passportDrug Testing and Analysis, 2020
- Transcriptomic biomarkers of altered erythropoiesis to detect autologous blood transfusionDrug Testing and Analysis, 2017
- Impact of blood transfusion on gene expression in human reticulocytesAmerican Journal of Hematology, 2016